TAAR1 and schizophrenia: Although the mechanism of action of ulotaront in the treatment of schizophrenia is not fully elucidated, preclinical studies suggest that activation of TAAR1 may normalize hyperdopaminergic activity by decreasing presynaptic dopamine synthesis capacity, release, and/or neuronal firing [31].